Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial

This publication has 30 references indexed in Scilit:

• The EUROPA trial
  The Lancet, 2003
• Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
  New England Journal of Medicine, 2000
• Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
  Circulation, 1994
• Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty).
  Circulation, 1993
• Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)
  Annals of Internal Medicine, 1993
• Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
  Circulation, 1993
• Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
  New England Journal of Medicine, 1992
• Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
  New England Journal of Medicine, 1991
• Overview of Results of Randomized Clinical Trials in Heart Disease
  JAMA, 1988
• A Randomized Trial of Propranolol in Patients With Acute Myocardial Infarction
  JAMA, 1982